Mebendazole chewable tablets - Janssen

Drug Profile

Mebendazole chewable tablets - Janssen

Alternative Names: Vermox

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Janssen
  • Class Anthelmintics; Benzimidazoles
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Helminthiasis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Helminthiasis

Most Recent Events

  • 19 Oct 2016 Efficacy data from a phase II/III study in Helminthiasis released by Janssen
  • 19 Oct 2016 Registered for Helminthiasis in USA (PO) in October 2016
  • 19 Oct 2016 Mebendazole chewable tablets - Janssen receives Orphan Drug status for Helminthiasis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top